The performance of companies tied to Viagra's legacy presents a complex investment picture . While the initial success generated substantial profits , generic alternatives have significantly impacted revenue. Investing in associated pharmaceutical businesses now requires a discerning assessment of patent safeguards, evolving medical trends , and th